Chemotherapy (MVPP) for Stage IIIB/IV Hodgkin’s disease with an assessment of prognostic factors

  • W. P. Steward
  • J. Wagstaff
  • I. D. Todd
  • D. Crowther
Part of the Developments in Oncology book series (DION, volume 32)


Of all patients presenting with Hodgkin’s disease, in excess of 30% will have Clinical Stage (CS) IIIB or IV disease or will be found to have Pathologic Stage (PS) IIIB/IV disease following staging laparotomy. Prior to the use of combination chemotherapy with mustine, vincristine, procarbazine and prednisolone (MOPP) [1], the prognosis for such patients was bleak. With the advent of the MOPP regimen a high percentage of durable complete remissions could be obtained. The dramatic improvement in survival for these patients has, however, led to a popular misconception that advanced stage Hodgkin’s Disease is a readily curable malignancy. Unfortunately, despite drug and dosage alterations, little advance has been made in the 20 years since the introduction of MOPP and 30–40% of patients will die using currently available therapy [2–4].


Complete Remission Remission Status Durable Complete Remission Total Patient Group Curable Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeVita VT and Serpick A (1967). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Amer Assoc Cancer Res 8:13.Google Scholar
  2. 2.
    Frei E III, Luce JK, Gamble JF et al. (1973). Combination chemotherapy in advanced Hodgkin’s disease: Induction and maintenance of remission. Ann Intern Med 79:376382.Google Scholar
  3. 3.
    Moore MR, Jones SE, Bull JM et al. (1973). MOPP chemotherapy for advanced Hodgkin’s disease - prognostic factors in 81 patients. Cancer 32:52–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonadonna G, Zucali R, Monfardini S et al. (1975). Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36:252–259.Google Scholar
  5. 5.
    Sutcliffe SB, Wrigley PFM, Peto J et al. (1978). MVPP chemotherapy regimen for advanced Hodgkin’s disease. Brit Med J 1:679–683.PubMedCrossRefGoogle Scholar
  6. 6.
    Crowther D (1981). Hodgkin’s disease: A curable malignancy. Clin Radiol 32:241–250.PubMedCrossRefGoogle Scholar
  7. 7.
    Pederson-Bjergaard J and Larsen SO (1982). Incidence of acute non-lymphocytic leukaemia, pre-leukaemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med 307:965–971.CrossRefGoogle Scholar
  8. 8.
    Coltman CA Jr. and Dixon DO (1982). Second malignancies complicating Hodgkin’s disease: A Southwest Oncology Group 10-year follow up. Cancer Treat Rep 66: 1023–1029.PubMedGoogle Scholar
  9. 9.
    Krikorian J, Portlock GS, Robertson A et al. (1978). Treatment of advanced Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer 41:2107–2111.PubMedCrossRefGoogle Scholar
  10. 10.
    Porzig K, Portlock C, Robertson A et al. (1978). Treatment of advanced Hodgkin’s disease with B-CAVe following MOPP failure Cancer 41:1670–1675.Google Scholar
  11. 11.
    Young R, Canellos G, Chabner B et al. (1978). Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer 42:1001–1007.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan EL and Meier P (1958). Non-parametric estimation from incomplete observations. Amer Stat Assoc J 53:457–481.CrossRefGoogle Scholar
  13. 13.
    Peto R and Peto J (1972). Asymptotically efficient rank invariant test procedures. J Royal Statist Soc A. 35:185–207.CrossRefGoogle Scholar
  14. 14.
    Cox DR (1972). Regression models and life tables. J Roy Stat Soc B. 34: 187–220.Google Scholar
  15. 15.
    DeVita VT, Simon RM, Hubbard SM et al. (1980). Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92:587–595.PubMedGoogle Scholar
  16. 16.
    Coltman CA (1981). Chemotherapy of advanced Hodgkin’s disease. Semin Oncol 7:155–173.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • W. P. Steward
    • 1
  • J. Wagstaff
    • 1
  • I. D. Todd
    • 2
  • D. Crowther
    • 1
  1. 1.Departments of Medical OncologyChristie Hospital and Holt Radium InstituteManchesterUK
  2. 2.Departments of RadiotherapyChristie Hospital and Holt Radium InstituteManchesterUK

Personalised recommendations